Foundational characteristics of cancer include proliferation, angiogenesis, migration, evasion of apoptosis, and cellular immortality. Find key markers for these cellular processes and antibodies to detect them.
The SUMOplot™ Analysis Program predicts and scores sumoylation sites in your protein. SUMOylation is a post-translational modification involved in various cellular processes, such as nuclear-cytosolic transport, transcriptional regulation, apoptosis, protein stability, response to stress, and progression through the cell cycle.
The Autophagy Receptor Motif Plotter predicts and scores autophagy receptor binding sites in your protein. Identifying proteins connected to this pathway is critical to understanding the role of autophagy in physiological as well as pathological processes such as development, differentiation, neurodegenerative diseases, stress, infection, and cancer.
MAP3K13 (LZK) Antibody
Mouse Monoclonal Antibody (Mab)
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application 
| WB, IF, E |
|---|---|
| Primary Accession | O43283 |
| Reactivity | Human |
| Host | Mouse |
| Clonality | Monoclonal |
| Isotype | IgM |
| Clone/Animal Names | 810CT26.6.1.1 |
| Calculated MW | 108296 Da |
| Antigen Region | 52-305 aa |
| Gene ID | 9175 |
|---|---|
| Other Names | Mitogen-activated protein kinase kinase kinase 13, Leucine zipper-bearing kinase, Mixed lineage kinase, MLK, MAP3K13 (HGNC:6852) |
| Target/Specificity | Purified His-tagged MAP3K13 protein fragment was used to produced this monoclonal antibody. |
| Dilution | IF~~1:100 WB~~1:500 |
| Format | Purified monoclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is prepared by Euglobin precipitation followed by dialysis against PBS. |
| Storage | Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles. |
| Precautions | MAP3K13 (LZK) Antibody is for research use only and not for use in diagnostic or therapeutic procedures. |
| Name | MAP3K13 (HGNC:6852) |
|---|---|
| Function | Activates the JUN N-terminal pathway through activation of the MAP kinase kinase MAP2K7. Acts synergistically with PRDX3 to regulate the activation of NF-kappa-B in the cytosol. This activation is kinase-dependent and involves activating the IKK complex, the IKBKB- containing complex that phosphorylates inhibitors of NF-kappa-B. |
| Cellular Location | Cytoplasm. Membrane; Peripheral membrane protein |
| Tissue Location | Expressed in the adult brain, liver, placenta and pancreas, with expression strongest in the pancreas |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
Activates the JUN N-terminal pathway through activation of the MAP kinase kinase MAP2K7. Acts synergistically with PRDX3 to regulate the activation of NF-kappa-B in the cytosol. This activation is kinase-dependent and involves activating the IKK complex, the IKBKB-containing complex that phosphorylates inhibitors of NF-kappa-B.
References
Ikeda A., et al. J. Biochem. 130:773-781(2001).
Masaki M., et al. Eur. J. Biochem. 270:76-83(2003).
Greenman C., et al. Nature 446:153-158(2007).
Sakuma H., et al. J. Biol. Chem. 272:28622-28629(1997).
Ota T., et al. Nat. Genet. 36:40-45(2004).
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.
Ordering Information
Other Products
Shipping Information
